{
    "clinical_study": {
        "@rank": "82556", 
        "brief_summary": {
            "textblock": "This non-randomized study will test the safety and effectiveness of Genasense in patients\n      with CLL."
        }, 
        "brief_title": "Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia", 
        "condition": [
            "Chronic Lymphocytic Leukemia", 
            "CLL"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is a two-part phase I-II study. Part 1 will determine the MTD of Genasense in\n      patients with CLL. This dose will then be tested in a non-randomized, multi-center, Phase II\n      sequential clinical trial of Genasense used alone for treatment of patients with advanced\n      CLL.\n\n      Pharmacokinetics of Genasense and kinetics of Bcl-2 down regulation and re-expression in CLL\n      cells will be followed in selected patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  Any age\n\n          -  Must have received at least one chemotherapy regimen that included fludarabine\n\n          -  Measurable disease\n\n          -  At least 3 weeks since biological therapy or radiation therapy for chronic\n             lymphocytic leukemia\n\n          -  No previous stem cell transplantation\n\n          -  At least 3 weeks since surgery"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 3, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_alias": "NCT00021190", 
            "nct_id": "NCT00021749", 
            "org_study_id": "GL208", 
            "secondary_id": [
                "G3139", 
                "Bcl-2 Antisense"
            ]
        }, 
        "intervention": {
            "intervention_name": "Oblimerson sodium, G3139", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "CLL", 
            "Leukemia", 
            "Chronic", 
            "Cancer", 
            "Adult", 
            "Lymphocytic", 
            "Genasense", 
            "G3139", 
            "Genta", 
            "Bcl-2", 
            "Antisense", 
            "Oligonucleotide", 
            "oblimerson"
        ], 
        "lastchanged_date": "November 10, 2009", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "New Hyde Park", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Long Island Jewish Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "MD Anderson Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "San Antonio Cancer Institute"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I-II Multicenter Study of Genasense (Bcl-2 Antisense Oligonucleotide) in Patients With Advanced Chronic Lymphocytic Leukemia", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "January 2003", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00021749"
        }, 
        "results_reference": {
            "PMID": "16186597", 
            "citation": "O'Brien SM, Cunningham CC, Golenkov AK, Turkina AG, Novick SC, Rai KR. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol. 2005 Oct 20;23(30):7697-702. Epub 2005 Sep 26."
        }, 
        "source": "Genta Incorporated", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genta Incorporated", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2001", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2009"
    }, 
    "geocoordinates": {
        "Long Island Jewish Medical Center": "40.735 -73.688", 
        "MD Anderson Cancer Center": "29.76 -95.369", 
        "San Antonio Cancer Institute": "29.424 -98.494"
    }
}